The Role of miRNA in Testicular Cancer: Current Insights and Future Perspectives
Authors:
- Francesco DitonnoFDFrancesco Ditonno
- Antonio FrancoAFAntonio Franco
- Celeste ManfrediCeleste Manfredi
- Daniela FasanellaDFDaniela Fasanella
- Marco AbateMAMarco Abate
- Roberto La RoccaRRRoberto La Rocca
- Fabio CrocerossaFCFabio Crocerossa
- Vincenzo IossaVIVincenzo Iossa
- Ugo Giovanni FalagarioUFUgo Giovanni Falagario
- Luigi CirilloLCLuigi Cirillo
- Vincenzo Maria AltieriVAVincenzo Maria Altieri
- Ernesto Di MauroEMErnesto Di Mauro
Open Access
Abstract
Background and Objectives: Despite advancements in the diagnosis and treatment of testicular germ cell tumours (TGTCs), challenges persist in identifying reliable biomarkers for early detection and precise disease management. This narrative review addresses the role of microRNAs (miRNAs) as potential diagnostic tools and therapeutic targets in the treatment of TGCTs. Materials and Methods: Three databases (PubMed®, Web of Science™, and Scopus®) were queried for studies investigating the utility of miRNA as diagnostic tools, assessing their prognostic significance, and evaluating their potential to guide TGCT treatment. Different combinations of the following keywords were used, according to a free-text protocol: “miRNA”, “non-coding RNA”, “small RNA”, “Testicular Cancer”, “seminomatous testicular germ cell”, “non-seminomatous testicular germ cell”. Results: The potential of miRNAs as possible biomarkers for a non-invasive diagnosis of TGCT is appealing. Their integration into the diagnostic pathway for TGCT patients holds the potential to enhance the discriminative power of conventional serum tumour markers (STMs) and could expedite early diagnosis, given that miRNA overexpression was observed in 50% of GCNIS cases. Among miRNAs, miR-371a-3p stands out with the most promising evidence, suggesting its relevance in the primary diagnosis of TGCT, particularly when conventional STMs offer limited value. Indeed, it demonstrated high specificity (90–99%) and sensitivity (84–89%), with good positive predictive value (97.2%) and negative predictive value (82.7%). Furthermore, a direct relationship between miRNA concentration, disease burden, and treatment response exists, regardless of disease stages. The initial evidence of miRNA decrease in response to surgical treatment and systemic chemotherapy has been further supported by more recent results suggesting the potential utility of this tool not only in evaluating treatment response but also in monitoring residual disease and predicting disease relapse. Conclusions: MiRNAs could represent a reliable tool for accurate diagnosis and disease monitoring in the treatment of TGCT, providing more precise tools for early detection and treatment stratification. Nevertheless, well-designed clinical trials and comprehensive long-term data are needed to ensure their translation into effective clinical tools.Keywords
This publication has 46 references indexed in Scilit:
- MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele FluidUrologia Internationalis, 2016
- A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumoursBritish Journal of Cancer, 2015
- Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell CancerJournal of Urology, 2015
- Recent trends in the incidence of testicular germ cell tumors in the United StatesAndrology, 2014
- Targeted serum miRNA (TSmiR) test for diagnosis and follow‐up of (testicular) germ cell cancer patients: A proof of principleMolecular Oncology, 2013
- MicroRNA expression profiles of seminoma from paraffin-embedded formalin-fixed tissueVirchows Archiv, 2012
- MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumoursBritish Journal of Cancer, 2012
- MicroRNA expression profiling of carcinoma in situ cells of the testisEndocrine-Related Cancer, 2012
- Identification of MicroRNAs From the miR-371∼373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell TumorsAmerican Journal of Clinical Pathology, 2011
- High‐throughput microRNAome analysis in human germ cell tumoursThe Journal of Pathology, 2007